{"id":"W4403228604","doi":"10.1038/s41591-024-03270-6","title":"Sustained effect of prasinezumab on Parkinson’s disease motor progression in the open-label extension of the PASADENA trial","year":2024,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Montreal Neurological Institute and Hospital","funders":"Sanofi Genzyme; Feinberg School of Medicine; Allergan; Genentech; National Institutes of Health; Mitsubishi Tanabe Pharma Corporation; Servier; Eisai; Newcastle University; University of Exeter; Parkinson's UK; Voyager Therapeutics; Jazz Pharmaceuticals; Prothena; Denali Therapeutics; Neurocrine Biosciences; Weston Brain Institute; H. Lundbeck A/S; Deutsches Zentrum für Neurodegenerative Erkrankungen; Sunovion; Deutsche Forschungsgemeinschaft; Roche; McGill University; Michael J. Fox Foundation for Parkinson's Research; Boston Scientific Corporation; Pfizer; Northwestern University; Biogen; Parkinson's Foundation; Celgene; Verily Life Sciences; Teva Pharmaceutical Industries; Sanofi; Parkinson Canada; F. Hoffmann-La Roche; GlaxoSmithKline; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Placebo; Parkinson's disease; Medicine; Rating scale; Internal medicine; Levodopa; Disease; Motor symptoms; Psychology; Physical therapy; Physical medicine and rehabilitation; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001129062,0.0002810057,0.0006026729,0.0002091963,0.00006803682,0.00001526272,0.0003885432,0.000205353,0.00004453575],"category_scores_gemma":[0.001496342,0.0001063954,0.0001237608,0.0007084986,0.0001495991,0.00006132043,0.0001362878,0.0006905705,0.000002703478],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001186297,"about_ca_system_score_gemma":0.0002472228,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002316238,"about_ca_topic_score_gemma":0.000004125839,"domain_scores_codex":[0.9974155,0.0004157386,0.000411913,0.0004455039,0.001063761,0.0002475231],"domain_scores_gemma":[0.9983019,0.0005425612,0.0001642222,0.0007416716,0.0001006588,0.0001490436],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6522616,0.01060269,0.01215664,0.006246806,0.0009054916,0.005613352,0.001804754,0.000003513182,0.03443246,0.008228355,0.03437474,0.2333696],"study_design_scores_gemma":[0.5001169,0.05640417,0.2745039,0.03649238,0.005449931,0.000128445,0.0005100504,0.002362818,0.02745806,0.003924805,0.0919873,0.0006612569],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9636368,0.01787248,0.000005138552,0.01102539,0.001168789,0.005405876,0.00004115193,0.00003489661,0.0008094969],"genre_scores_gemma":[0.9981342,0.00012722,0.00003316818,0.000662797,0.0004097761,0.0002326274,0.00005233006,0.00003111816,0.0003167943],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2623473,"threshold_uncertainty_score":0.4338678,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01829417493526915,"score_gpt":0.3593214530867688,"score_spread":0.3410272781514997,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}